Skip to main content

Monoclonal Antibody Infusion Treatment

Covid-19

Monoclonal Antibody Infusion Treatment

AU Health is now offering Bamlanivimab Infusions for high risk patients recently diagnosed with COVID-19.

1120 15th Street
Augusta, Georgia 30912
706-721-9449
Refer a Patient

  • Monoclonal Antibody Infusion Treatment

Bamlanivimab must be administered within 10 days of symptom onset (preferably <5 days) and as soon as possible after a positive viral test for SARS-CoV-2.

Bamlanivimab must be administered within 10 days of symptom onset (preferably <5 days) and as soon as possible after a positive viral test for SARS-CoV-2.

Patient must have a positive COVID-19 test.
  1. The patient must MEET AT LEAST ONE criteria below for being at high risk of developing severe COVID:
    1. BMI greater than or equal to 35
    2. Chronic kidney disease (CKD)
    3. Diabetes
    4. Immunosuppressive disease
    5. Currently receiving immunosuppressive treatment
    6. Age 65 years old or older
    7. Age 55 years old or older with cardiovascular disease
    8. Age 55 years old or older with hypertension
    9. Age 55 years old or older with chronic obstructive pulmonary disease
    10. Age 12-17 years old with BMI greater than or equal to the 85th percentile for age/gender
    11. Age 12-17 years old with Sickle cell disease
    12. Age 12-17 years old with Congenital or acquired heart disease
    13. Age 12-17 years old with Neurodevelopmental disorders
    14. Age 12-17 years old with Medical-related technology dependence (tracheostomy, gastrostomy, positive pressure ventilation, )
    15. Age 12-17 years old with Asthma
    16. Age 12-17 years old with Reactive airway or other chronic respiratory disease requiring treatment
  2. The patient DOES NOT MEET any of the exclusion criteria/limitations of authorized use under the Bamlanivimab EUA per below:
    1. Hospitalized due to COVID-19
    2. Require oxygen therapy due to COVID-19
    3. Require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID related comorbidity
  3. This patient is at least 12 years old and weighs at least 40 kg with a positive result for SARS- CoV-2 and meets the criteria for being at high risk of developing severe COVID-19 as documented above.
  1. Patient must meet the inclusion criteria
  2. Patient must have the following information readily available
    1. Patient Name
    2. DOB
    3. Patient Mobile # (to initiate Virtual Care visit)
    4. Patient Email
    5. Date of + COVID-19 Result
    6. Date of Symptom Onset
  3. Patient will be screened via AU Health Virtual Care platform to verify infusion appropriateness, discuss the risks/benefits of the infusion and provide next steps
  4. A health care provider can make also make a referral by calling 706-721-9449.

Provider Referral Form

Detailed instructions for infusion treatment will be provided upon scheduling.

Benefit of treatment has not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies, such as Bamlanivimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation

video thumbnail
Monoclonal Antibody Infusion - Why, When & How

Resources & Tools.

Close
Close

Personalize your experience.

Select your preferences below, so we can deliver the most relevant content to you:

Close

Personalize your experience.

Select your preferences below, so we can deliver the most relevant content to you: